Time-to-treatment failure (TTF) with first-line afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm plus ) advanced non-small-cell lung cancer (NSCLC): Randomized phase IIb LUX-lung 7 (LL7) trial

Authors :: Schuler, M.
Tan, E-H
O Byrne, K.
Zhang, L.
Boyer, M.
Tony Mok
Hirsh, V.
Yang, J. C-H
Lee, K. H.
Lu, S.
Shi, Y.
Kim, S-W
Laskin, J.
Kim, D-W
Arvis, C. Dubos
Kolbeck, K.
Massey, D.
Fan, J.
Paz-Ares, L.
Park, K.
Source :: Web of Science, ResearcherID

Tools